The technology is intended to support imaging-based training, protocol optimisation and surgical planning
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
The company introduced the ExcelSign E12 and E17 modular patient monitors, the Relife 1000 biphasic defibrillator, and a new OT charting software
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Subscribe To Our Newsletter & Stay Updated